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Summary Survival rates were analysed for a population-based series of over 15,000 childhood cancers
registered in Great Britain during 1971-85. There were highly significant improvements (P <0.001 for trend)
in survival for many major diagnostic groups. Between 1971-73 and 1983-85 the actuarial 5-year survival
rates increased from 37% to 70% for acute lymphoblastic leukaemia, from 4% to 26% for acute non-
lymphoblastic leukaemia, from 76% to 88% for Hodgkin's disease, from 22% to 70% for non-Hodgkin's
lymphoma, from 61% to 72% for astrocytoma, from 24% to 42% for medulloblastoma, from 15% to 43%
for neuroblastoma, from 58% to 79% for Wilms' tumour, from 17% to 54% for osteosarcoma, from 26% to
61% for rhabdomyosarcoma, from 59% to 94% for malignant testicular germ-cell tumours and from 43% to
77% for malignant ovarian germ-cell tumours. These increases in population-based survival rates reflect the
substantial advances in treatment of a wide range of childhood cancers since 1970. The two principal
diagnostic groups for which there was no.evidence of any trend were retinoblastoma, which already had an
excellent prognosis with a 5-year survival rate of over 85%, and Ewing's sarcoma, for which the survival rate
remained below 45%.
Until now, the only detailed analysis of survival rates for
childhood cancer using population-based data from the
whole of Great Britain was that covering children registered
during 1962-70, with a brief addendum for 1971-74 (Draper
et al., 1982). Survival rates during the 1960s were generally
low. Of the major diagnostic groups, only retinoblastoma,
Hodgkin's disease, astrocytoma, craniopharyngioma and
fibrosarcoma had a 5-year survival rate of over 50%. The
5-year survival rate for childhood leukaemia was only around
10% towards the end of the decade. Since then, there have
been advances in the treatment of many types of childhood
cancer, which might be expected to result in markedly im-
proved survival rates. For some diagnostic groups, im-
provements in survival have also been shown to be associated
with increased centralisation of treatment (Stiller, 1988a;
Stiller & Draper, 1989). Survival rates have been published
from population-based childhood cancer registries in two
Health Regions (Craft et al., 1987; Birch et al., 1988) but
these regions are not typical as they both have very well-
established patterns of centralised treatment for childhood
cancer.
In this paper we present survival rates for Britain as a
whole for children diagnosed during 1971-85. The reasons
for trends in the survival rates for the various diagnostic
groups will be discussed. Survival rates have also been
published from a few population-based registries in other
countries and these will be compared with the results from
Britain.
Patients and methods
The National Registry of Childhood Tumours at the Child-
hood Cancer Research Group (CCRG) includes children who
were domiciled in England, Scotland or Wales and aged
under 15 at the time of diagnosis with a malignant neoplasm
or certain other types of tumour. The principal sources of
ascertainment are the National Cancer Registration Schemes
which cover the whole of Britain through a network of
regional registries. Children have also been ascertained from
local population-based childhood cancer registries in several
regions, from entries to the Medical Research Council
leukaemia trials and, since 1977, from the register of patients
treated by members of the United Kingdom Children's
Cancer Study Group (UKCCSG). The Registry also receives
death certificates for all deaths occurring in Britain under the
age of 20 and with a neoplasm coded as the underlying
cause.
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About 5 years from diagnosis the medical records of child-
ren in the Registry are checked in order to confirm the
diagnosis and obtain a brief outline of treatment and follow-
up. The survivors are flagged in the National Health Service
Central Registers (NHSCR) so that CCRG will be notified of
any further deaths and of embarkations resulting in loss to
follow-up.
The patients included in the present study are all those
children in the Registry who were diagnosed during 1971-85,
except that those ascertained by death certificate alone have
been excluded since unregistered survivors could not have
been ascertained. Some cancer registrations for 1985 have not
yet been received but we believe that over 90% of cases from
that year have been ascertained. A few diagnoses from 1985
have also not yet been checked, though it is very unlikely
that there are many major changes still to be recorded.
The diagnoses are coded according to the International
Classification of Diseases for Oncology (ICD-O). Childhood
tumours occur in a wide variety of histological types, several
of which are seen only very rarely in adults. A classification
based mainly on primary site such as the ICD is thus inap-
propriate for childhood cancer. We have used the classifi-
cation scheme which was developed for a recent study of
international childhood cancer incidence (Parkin et al., 1988).
The definitions of the individual categories by ICD-O codes
are given in that volume and in a paper describing the
scheme (Birch & Marsden, 1987). We have modified the
scheme by combining categories in a few instances. (i) The
very few cases of unspecified lymphoid leukaemia in the
Registry are almost certainly acute lymphoblastic leukaemia
(ALL) and they have been included with ALL here. There
were no cases of chronic lymphatic leukaemia. (ii) Non-
Hodgkin's, Burkitt's and unspecified lymphomas have been
combined. The distinction between non-Hodgkin's and Bur-
kitt's lymphoma is hard to make in the Registry, especially
for earlier years of diagnosis. It was felt that cases of uns-
pecified lymphoma were very unlikely to be Hodgkin's
disease. (iii) 'Other glioma' and miscellaneous intracranial
and intraspinal neoplasms have been combined. Many of
these tumours have not been histologically confirmed and the
distinction between unspecified, unverified glioma and uns-
pecified, unverified tumour seemed artificial.
There are also a few well-defined histological types which
are not allocated specific codes in ICD-O. We have assigned
them to categories as follows: (i) Intracranial primitive
neuroectodermal tumour (PNET) is classified with medullo-
blastoma, group 111(c). (ii) Peripheral neuroectodennal
tumours have been included with other soft-tissue sarcoma,
group IX(c). There were no recorded cases of neuroectoder-
mal tumours of bone. (iii) Rhabdoid renal tumour and bone-
metastasing renal tumour of childhood have both been
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classified with Wilms' tumour, group V(a). (iv) Pancreatico-
blastoma has been included with other malignant neoplasms,
group XII.
Acute megakaryocytic leukaemia (FAB M7) has been
transferred from 'other and unspecified' to acute non-
lymphocytic leukaemia. Histiocytosis X, or Langerhans Cell
histiocytosis, has not been included because it is not currently
regarded as a cancer and furthermore ascertainment is very
incomplete.
The categories used in our analyses are listed in Table I. A
few of the categories of other and unspecified tumours
included some well-defined sub-groups of particular interest
and these have also been considered separately.
For this study, follow-up of survivors through flagging at
NHSCR and the routine receipt of death certificates was
virtually complete to the end of 1988.
Survival rates were calculated by standard actuarial
methods. Differences between the survival curves were tested
by log-rank tests and the x2 test for linear trends.
Results
Table I shows the total numbers of registrations analysed for
each major diagnostic group together with the actuarial 5-
year survival rates for children registered in the five succes-
sive triennia from 1971-73 to 1983-85 and the result of a x2
test for linear trend in the survival curves. While for some
(a), (b) Acute lymphocytic and other lymphoid
leukaemias
(c) Acute non-lymphocytic leukaemia
(d) Chronic myeloid leukaemia
(e) Other and unspecified leukaemia
II Lymphomas
(a) Hodgkin's disease
(b), (c), (d) Non-Hodgkin's, Burkitt's and
unspecified lymphomas
4993
1052
145
141
857
1128
childhood cancers 5-year survival may be regarded as almost
equivalent to cure, for others there is an appreciable risk of
death for many years after diagnosis. We have therefore also
calculated 10-year survival rates for children diagnosed dur-
ing 1971-79 and 15-year rates for those diagnosed during
1971-73; these rates are given in Table II. Actuarial survival
curves for the five triennia ofdiagnosis for selected diagnostic
groups are shown in Figures 1-12.
Leukaemia
There was a highly significant improvement in the survival
rate for ALL (Figure 1). Girls have generally had a better
prognosis than boys, and children aged 2-9 also had a
higher survival rate. As shown in Table III, both sexes and
all age groups shared in the improvement in survival. By
1983-85 the difference in 5-year survival between the sexes
had disappeared. There was a substantial number of deaths
among children with ALL more than 5 years after diagnosis;
the improvement in survival during the 1970s persisted until
at least 10 years after diagnosis.
Survival rates for acute non-lymphocytic leukaemia
(ANLL) were consistently lower than for ALL (Figure 2).
There was nevertheless a significant trend towards higher
rates for children diagnosed more recently, with the largest
improvement occurring between 1974-76 and 1977-79. For
children diagnosed before 1977 there was, however, hardly
any mortality more than 4 years from diagnosis, whereas for
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III CNS and miscellaneous intracranial and intraspinal neoplasms
(a) Ependymoma 523
(b) Astrocytoma 1606
(c) Medulloblastoma 899
(d), (e) Other and misc. intracranial and 1380
intraspinal neoplasms
IV Sympathetic nervous system tumours
(a) Neuroblastoma and ganglioneuroblastoma
V Retinoblastoma
VI Renal tumours
(a) Wilms' tumour
VII Hepatic tumours
(a) hepatoblastoma
VIII Malignant bone tumours
(a) Osteosarcoma
(c) Ewing's sarcoma
IX Soft-tissue sarcomas
(a) Rhabdomyosarcoma, embryonal sarcoma and
soft-tissue Ewing's tumour
(b) Fibrosarcoma, neurofibrosarcoma and other
fibromatous neoplasms
(c) Other soft-tissue sarcoma
X Germ-cell, trophoblastic and other gonadal neoplasms
(a) Gonadal germ-cell and trophoblastic
neoplasms
(i) Testicular
(ii) Ovarian
XI Epithelial neoplasms
(b) Thyroid carcinoma
(c) Nasopharyngeal carcinoma
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40
29
61
36
39
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65
37
47
54
72
42
45
5.0
15.2
14.2
4.9
15 19 25 37 43 104.8
504 87 88 89 86 91 0.6
58 64 76 76 79 32.5
8 21 17 30 40 4.8
519 17 24 28 34 54 36.4
373 39 38 34 34 42 1.5
769 26 40 46 48 61 47.5
171 69 37 54 71 63 0.7
236 38 46 61 54 44 3.2
144 59 63 69 84 94 14.4
135 43 45 74 85 77 12.3
76 100 100 94 100 100 0.8
60 67 33 75 63 60 0.2
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Table I 5-year actuarial survival rates for children diagnosed in successive 3-year periods, with result of test for trend on survival curves
Total 5-year survival rate (%) for years of diagnosis X2 (I df)
Diagnostic group registrations 1971-73 1974-76 1977-79 1980-82 1983-85 for trend
I Leukaemias
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Table II Ten and 15-year actuarial survival rates for children in successive 3-year periods
10-year survival rate (%) Fifteen year
for years of diagnosis survival rate (%)
Diagnostic group 1971-73 1974-76 1977-79 1971-73
I Leukaemias
(a), (b) Acute lymphocytic and other lymphoid 29
leukaemias
(c) Acute non-lymphocytic leukaemia 3
(d) Chronic myeloid leukaemia 9
(e) Other and unspecified leukaemia 6
II Lymphomas
(a) Hodgkin's disease 68
(b), (c), (d) Non-Hodgkin's, Burkitt's and 20
unspecified lymphomas
III CNS and miscellaneous intracranial and intraspinal neoplasms
(a) Ependymoma 35
(b) Astrocytoma 57
(c) Medulloblastoma 19
(d), (e) Other gliomas and misc. intracranial and 33
intraspinal neoplasms
IV Sympathetic nervous system tumours
(a) Neuroblastoma and ganglioneuroblastoma
V Retinoblastoma
VI Renal tumours
(a) Wilms' tumour
VII Hepatic tumours
(a) Hepatoblastoma
VIII Malignant bone tumours
(a) Osteosarcoma
(c) Ewing's sarcoma
IX Soft-tissue sarcomas
(a) Rhabdomyosarcoma, embryonal sarcoma and
soft-tissue Ewing's tumour
(b) Fibrosarcoma, neurofibrosarcoma and other
fibromatous neoplasms
(c) Other soft-tissue sarcomas
X Germ-cell, trophoblastic and other gonadal neoplasms
(a) Gonadal germ-cell and trophoblastic
neoplasms
(i) testicular
(ii) ovarian
XI Epithelial neoplasms
(b) Thyroid carcinoma
(c) Nasopharyngeal carcinoma
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Figure 2 Actuarial survival curves for children with acute non-
lymphocytic leukaemia diagnosed 1971-85.
Figure 1 Actuarial survival curves for children with acute yym-
phocytic leukaemia diagnosed 1971-85.
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Table III 5-year actuarial survival rates for children diagnosed as having acute
lymphocytic leukaemia in successive 3-year periods
5-year survival rate (%) for years of diagnosis X2 (Idf
Registrations 1971-73 1974-76 1977-79 1980-82 1983-85 for trend
(a) Stratified by sex
Sex
Male 2881 32 42 52 61 69 220.6
Female 2112 43 54 54 69 70 86.0
(b) Stratified by age at diagnosis
Age
0 151 16 0 8 35 26 8.8
1 379 33 42 52 61 63 20.5
2-4 2099 43 50 60 74 82 200.0
5-6 748 40 49 60 70 74 49.8
7-9 729 35 54 47 61 66 29.2
10- 14 887 24 41 44 51 54 37.4
those diagnosed more recently a substantial risk of death
persisted for at least two further years. There was little
difference in prognosis between the sexes. Infants aged under
1 year had a lower survival rate but their outlook also
improved during the 15 years under review.
There was no significant trend in survival rates for chronic
myeloid leukaemia; around a fifth of the children survived
for 5 years but the longer term survival was very low indeed.
Most of the remaining 141 children had leukaemia of
unspecified cell type. There was considerable variation in the
numbers registered during successive triennia. The survival
rate was markedly higher for the children diagnosed most
recently. There was little difference in prognosis between the
sexes. As with ALL and ANLL, the rate was particularly low
for infants aged under 1 year.
Lymphoma
Survival rates for Hodgkin's disease improved significantly
from 75% at 5 years for children diagnosed in 1971-73 to
around 90% for those diagnosed from 1977 onwards.
Overall, boys had a better prognosis than girls, largely
because the lymphocyte predominant subtype, which has a
good prognosis, was more common in boys; however, the
survival rate for girls showed a greater improvement and had
slightly exceeded that for boys by 1983-85. Children aged
under 5 years or 12 years and over had a worse prognosis,
but the improvement in survival rates took place in all age
groups. There were substantial numbers of deaths more than
5 years after diagnosis, but among 5-year survivors the risk
of death during the following 5 years was halved between
1971-73 and 1977-79.
Survival rates for non-Hodgkin's lymphomas (NHL) were
markedly lower than for Hodgkin's disease, but there was a
very highly significant improvement over the 15-year period
which was especially marked from 1977 onwards (Figure 3).
Survival rates were similar for the two sexes and all age
groups except for infants under 1 year of age, who had a
lower survival rate. There were only 22 registrations for this
age group, with no clear trend.
Central nervous system (CNS) tumours
There were significant trends in survival rates for all
categories of CNS tumours. Overall, survival rates were
unchanged until the mid 1970s (Figure 4). Thereafter there
was a steady improvement, especially in survival rates more
than a few months after diagnosis.
For ependymoma there was little change until 1983-85;
children diagnosed during these years showed a substantial
improvement, with a particularly pronounced reduction in
mortality beyond 3 years after diagnosis.
The trend for astrocytoma was predominantly among
younger children, and especially infants, though the prog-
nosis for this age group was still worse than for older child-
ren by the end of the study period.
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Figure 3 Actuarial survival curves for children with non-
Hodgkin's, Burkitt's and unspecified lymphoma diagnosed
1971 -85.
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Figure 4 Actuarial survival curves for children with CNS and
miscellaneous intracranial and intraspinal neoplasms diagnosed
1971 -85.
Survival rates for medulloblastoma were higher among
older children. The prognosis was especially poor for infants
and, in contrast to older children, there was no improvement
in their survival rate until 1983-85; the numbers of registra-
tions at age under 1 year were small and the trend was not
significant.
The small but significant improvement in survival for the
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heterogenous category of other gliomas and miscellaneous
intracranial and intraspinal tumours was confined to boys.
Within this diagnostic group, there are several well-defined
types of tumour. For gliomas and unspecified tumours of the
brain stem, survival rates were generally low (under 20% at 5
years) and, although the prognosis had improved in the latter
years of the study, the trend was not significant. The prog-
nosis for craniopharyngioma was much better and improved
further during the period under review (5-year survival rates
were 89% for 1983-85 as opposed to 65% for 1971-73).
For pineal tumours, although the survival rates fell in the
middle years of the study, there was very little overall
change: 5-year survival rates were 50% for 1971-73 and
52% for 1983-85.
Sympathetic nervous system
There was a highly significant improvement in survival rates
for neuroblastoma and ganglioneuroblastoma (Figure 5),
although by 1983-85 the prognosis was still poor in com-
parison to those for many other diagnostic groups. As shown
in Table IV, the prognosis worsened with increasing age at
diagnosis but there was a significant trend in survival during
the study period for all age groups.
There were 22 registrations for miscellaneous other malig-
nant tumours of the sympathetic nervous system (eight
medulloepithelioma or neuroepithelioma, six olfactory
tumours, four paraganglioma and four phaeochromo-
cytoma); their 5-year survival rate was 46%.
Retinoblastoma
Survival rates were already high by 1971 and there was no
further improvement during the study period.
Renal tumours
Survival rates for Wilms' tumour rose significantly, especially
in the period before 1980 (Figure 6). The prognosis was
significantly better for boys and children aged under 5 years.
The improvement in survival rates applied to both sexes and
all ages except possibly for the small number ofchildren aged
10-14.
There were 22 registrations for renal carcinoma, with a
5-year survival rate of 55%. There were only four registra-
tions for other and unspecified renal tumours.
Hepatic tumours
For hepatoblastoma there was a significant trend in survival
rates with year of diagnosis. No deaths have been observed
more than 5 years after diagnosis. There were 38 registrations
for hepatocellular carcinoma. The 5-year survival rate was
13%, with no evidence of any trend. There were no registra-
tions for other and unspecified hepatic tumours.
Malignant bone tumours
There was a highly significant increase in survival rates for
osteosarcoma, with the improvement being especially marked
between 1980-82 and 1983-85 (Figure 7). For Ewing's sar-
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Figure 5 Actuarial survival curves for children with neuro-
blastoma and ganglioneuroblastoma diagnosed 1971 -85.
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Figure 7 Actuarial survival curves for children with osteosar-
coma diagnosed 1971-85.
Table IV 5-year actuarial survival rates for children with neuroblastoma, classified by age
at diagnosis
Age Total 5-year survival rate (%) for years of diagnosis X2 (Idf)
(years) registrations 1971-73 1974-76 1977-79 1980-82 1983-85 for trend
0 280 30 52 56 68 77 36.6
1 183 21 15 21 31 39 10.8
2 182 7 10 18 23 28 26.8
3 133 12 11 14 13 23 8.7
4 94 6 5 0 18 25 8.7
5-9 164 8 7 15 26 24 15.5
10- 14 70 7 13 19 67 44 9.7CHILDHOOD CANCER SURVIVAL 1971-85 811
Table V 5-year actuarial survival rates for children with rhabdomyosarcoma, classified by primary
site
Primary Total S-year survival rate (%) for years of diagnosis x2 (Idf)
site registrations 1971-73 1974-76 1977-79 1980-82 1983-85 for trend
Orbit 68 46 64 77 85 94 5.9
Nasopharynx 62 0 38 14 42 54 14.0
Head and neck 183 30 38 33 53 65 13.4
Upper limb 27 22 100 43 83 100 7.8
Lower limb 74 33 25 33 36 31 0.1
Bladder 56 33 38 55 46 82 4.4
Male genital 54 44 78 80 86 85 4.4
Female genital 28 17 67 100 33 88 6.7
Other pelvic 86 21 41 47 39 35 1.3
Thoracic 56 14 25 30 23 36 1.8
Other 75 16 17 13 25 52 11.5
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Figure 8 Actuarial survival curves for children with Ewing's
sarcoma of bone diagnosed 1971 -85.
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Figure 9 Actuarial survival curves for children with rhabdomyo-
sarcoma, embryonal sarcoma and soft tissue Ewing's tumour
diagnosed 1971 -85.
coma (Figure 8) there was no change in survival rates, which
remained between 34% and 42% at 5 years throughout the
study period; there were substantial numbers of deaths
beyond 5 years, and the 10-year survival rate overall was
31%. There were 22 registrations for chondrosarcoma, with a
5-year survival rate of 50%. Other bone tumours, mostly of
unspecified cell type, were registered in 37 children; the 5-
year survival rate was 32%.
Soft-tissue sarcomas
Rhabdomyosarcoma, the commonest childhood soft-tissue
sarcoma, showed a highly significant improvement in survival
(Figure 9). The survival rates for individual primary sites are
shown in Table V. Significant increases were seen for all sites
except the lower limbs, pelvis (non-genital) and thorax. The
improvement was most marked for tumours of the naso-
pharynx and head and neck.
For fibrosarcoma and related tumours (mostly malignant
fibrous histiocytoma and neurofibrosarcoma) there was no
overall trend in survival rates (Figure 10). The 5-year survival
rate for 1974-76, however, was substantially lower than
those for earlier or later years of diagnosis.
There were 36 registrations for synovial sarcoma, with a
5-year survival rate of 58%. For the 24 children with liposar-
coma the survival rate was 79% at 5 years, while for the 20
with leiomyosarcoma it was 55%. There were 156 children
with other, mainly unspecified, soft-tissue sarcomas. Their
5-year survival rate was 40%, with no evidence of any trend.
Germ-cell, trophoblastic and other gonadal neoplasms
The patterns of occurrence of gonadal germ-cell tumours
differ markedly between the sexes. Testicular tumours of
childhood are predominantly yolk-sac tumours occurring at
ages under 5 years, whereas ovarian tumours exhibit a wider
range of histological types and have their highest incidence in
the 10-14 age range. There were significant improvements in
survival rates for gonadal germ-cell tumours in both boys
(Figure 11) and girls (Figure 12). For testicular tumours the
improvement was greatest in the age range 1-2 years, while
for ovarian tumours it was most marked among girls aged
00
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Figure 10 Actuarial survival curves for children with fibrosar-
coma, neurofibrosarcoma and other fibromatous neoplasms diag-
nosed 1971-85.812 C.A. STILLER & K.J. BUNCH
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Figure 11 Actuarial survival curves for boys with malignant
testicular germ-cell tumours diagnosed 1971-85.
O Diagnosed 1 = 1971-73
o 2 = 1974-76
lao3
= 1977-79
h ~ ~ ~~~x 5= 1983--85
8No = 34
>,60 L
No = 21
40 No =30
20
1 2 3 4 5 6 7 8 9 1011121314151617181920
Years since diagnosis
Figure 12 Actuarial survival curves for girls with malignant
ovarian gern-cell tumours diagnosed 1971 -85.
13-14. The trend in survival for ovarian tumours was largely
attributable to a dramatic improvement occurring in girls
diagnosed around 1976-77.
The most common extragonadal sites for germ-cell
tumours were the CNS and the sacrococcygeal region. There
was no trend in survival for the 93 children with intra-cranial
tumours, but the results are difficult to interpret as the
numbers of registrations increased substantially from 1977
onwards. There was a highly significant trend among the 51
children with malignant sacrococcygeal tumours (x2 = 18.0
on 1 d.f., P <0.0001), with 5-year survival rates improving
from 10% in 1971-73 to 100% in 1983-85. No other sites
for germ-cell tumours had sufficient numbers for analysis.
There were only 5 boys and 12 girls with gonadal car-
cinoma and one boy and 10 girls with other malignant
gonadal tumours.
Epithelial neoplasms
Survival rates for thyroid carcinoma were uniformly high.
Nasopharyngeal carcinoma had a lower survival rate but
there was no sign of a trend; the unusually low 5-year
survival rate of 33% for patients with this tumour diagnosed
in 1974-76 was based on only 15 registrations. The 5-year
survival rate for the 37 children with adrenocortical car-
cinoma was 19%, with little evidence for any trend. Among
the 94 registered cases of skin carcinoma, only one death has
been recorded. The only other carcinomas occurring in sub-
stantial numbers were those of miscellaneous other sites in
the head and neck. There were 45 registrations, pre-
dominantly for tumours of the salivary glands. The 5-year
survival rate was 79%, and no later deaths have so far been
recorded.
Survival rates for malignant melanoma were not calculated
as the diagnosis has yet to be verified in a large proportion of
cases.
Discussion
Over the 15-year period covered by this study there were
substantial, statistically significant improvements in the prog-
nosis for most diagnostic groups, encompassing the great
majority of cases of childhood malignant disease. -
For most diagnostic groups there are few comparable data
from large population-based registries in other countries. The
largest series outside Britain is that of the United States
SEER Program for children diagnosed during 1973-81
(Young et al., 1986). In Table VI, 5-year survival rates for
several diagnostic groups from that series are compared with
those from the present study.
For children with ALL, the most common childhood
cancer, the probability of surviving 5 years from diagnosis
almost doubled between the early 1970s and mid 1980s. The
data relating to ALL have been discussed in more detail
elsewhere (Stiller & Draper, 1989). Over half of the children
treated during the study period were entered in the Medical
Research Council UKALL trials. Within the trials there was
little increase in survival rates during the 1970s, but a sub-
stantial improvement occurred during the 1980s (MRC,
1986a). The continuing improvement in the national series
throughout 1971-85 is attributable to an increase in the
proportion of children with ALL who were entered in the
trials or treated at hospitals seeing large numbers of children
with this disease (Stiller & Draper, 1989).
Survival rates during the 1970s were somewhat lower than
those observed in the United States; the 5-year survival rate
in the SEER Program was 59%, while for New York State
during 1973-78 the corresponding figure was 55% (Pole-
dnak, 1986). More recently, however, results in Britain have
been similar to those in other countries. Whites in the SEER
Program had a 3-year survival rate of 77% during 1981-84
(Steinhorn & Gloeckler Ries, 1988). In the Nordic countries
children diagnosed during 1981-85 had an actuarial survival
rate of 65% at 41 years from diagnosis after the exclusion of
the small, poor-prognosis subgroups of children with B-cell
ALL and infants aged under 1 year (Gustafsson et al., 1987).
In a large clinical trial series comprising more than half the
children with ALL in Italy during 1976-86, again omitting
B-cell ALL and infants as well as children with CNS involve-
ment at diagnosis, the 5-year survival rate was 65% (Paolucci
et al., 1989).
Table VI 5-year survival rates (%) for childhood cancer in Britain
and the United States, 1973-81
Britain United States
(present study) (Young et al., 1986)
Leukaemia 43 51
ALL 51 59
ANLL 12 20
Hodgkin's disease 86 84
NHL 36 51
Ependymoma 30 32
Astrocytoma 60 66
Medulloblastoma 33 41
Neuroblastoma 24 50
Retinoblastoma 87 88
Renal tumours, 70 76
Osteosarcoma 27 43
Ewing's sarcoma 36 48
Rhabdomyosarcomab 42 54
aUS data may include up to two cases ofparaganglioma. bUS data
exclude embryonal sarcoma.CHILDHOOD CANCER SURVIVAL 1971-85 813
In many large series, boys with ALL have been found to
have a worse prognosis than girls (Miller et al., 1983; Stein-
horn & Gloeckler Ries, 1988; Gustafsson et al., 1987). This
difference between the sexes was also observed in our data
until the most recent period; there had been a propor-
tionately greater improvement in survival rates for boys so
that by 1983-85 there was little difference between the sexes
in the proportions surviving 5 years. It has previously been
reported that the influence of sex on survival is greatest
during the first 15 months of complete remission but that
boys also suffer an excess of late relapses (Sather et al.,
1981). In the present series there was relatively little
difference between the sexes in the 1-year and 2-year survival
rates. The difference between the sexes in longer-term sur-
vival has, however, persisted: among children diagnosed dur-
ing 1980-82 who had survived 5 years, the mortality during
the next 4 years was 10% for boys but only 4% for girls. The
outlook for very young children aged under 2 with ALL, and
especially for infants diagnosed before the first birthday, has
always been poor (Cangir et al., 1975; Miller et al., 1983;
Leiper & Chessells, 1986). Although the relatively low sur-
vival rates for this age group persisted throughout the study
period, they did nevertheless show some improvement. This
improvement in survival with more intensive treatment has
also been reported from clinical studies (Reaman et al.,
1987). Since 1981 the UKALL trials have included larger
numbers of very young children, who thus now receive more
intensive chemotherapy than they did formerly, though with
CNS irradiation postponed until age 2.
Survival has been considerably lower among children with
ANLL, although there have been improvements, particularly
since the mid 1970s. Children with ANLL who were treated
at non-teaching hospitals during 1977-84 had a lower sur-
vival rate (Stiller, 1988a) and it is likely that the trend
towards treatment in specialist centres with widening
availability of bone marrow transplantation has contributed
to the improved survival rate nationally. Five-year survival
rates in the United States SEER registries were substantially
higher than in Britain for both 1973-76 (19%) and 1977-80
(25%) (Steinhorn & Gloeckler Ries, 1988).
Hodgkin's disease already had a relatively good prognosis
by 1971, and a significant further improvement has since
taken place. The survival rate nationally was slightly less
than the 94% at 5 years reported from two large oncology
centres during 1974-82 (Robinson et al., 1984). During
1970-84, 68 children with Hodgkin's disease were included
in the British National Lymphoma Investigation, a study in
which most of the patients are adults; the 5-year survival rate
for those children was 87% (Makepeace et al., 1987), very
similar to that nationally. Survival rates in Britain during
1973-81 were similar to those in the United States (Table
VI).
Clinical studies ofchildhood NHL, have been conducted in
Britain by the UKCCSG since 1977 (Mott et al., 1984a,b).
The most marked improvement in the prognosis for NHL
occurred from that date onwards. Since survival rates at
hospitals outside the UKCCSG have lagged behind those at
paediatric oncology centres (Stiller, 1988a), much of this
improvement can be ascribed to the UKCCSG studies. The
survival rate during the 1970s was markedly lower than in
the United States (Table VI).
The increase in survival rates from medulloblastoma
between 1971 and 1977 has been reported previously (Stiller
& Lennox, 1983), and was attributed to improvements in
post operative survival and increase in doses of radiotherapy.
The trend in survival rates since 1977 has been more modest.
The survival rates in the national series are appreciably lower
than those reported from large clinical trials (Allen et al.,
1986) but the trials did not include patients who died without
undergoing surgery or post-operatively. The population-
based survival rate was, however, also lower in Britain than
in the United States (Table VI) for medulloblastoma. For
ependymoma and astrocytoma, rates in the two countries
were very similar.
Compared with other diagnostic groups there was an
unusually high mortality many years after diagnosis for
patients with CNS tumours, with no sign of a plateau in the
survival curves. Of the 52 deaths so far recorded among
10-year survivors, death certificates indicated that 36 (71%)
were due to recurrent tumour, four (8%) to a second neo-
plasm and 11 (22%) to other causes. These proportions are
very similar to those found among 112 deaths occurring
10-19 years after diagnosis in childen who had CNS
tumours diagnosed before 1971 (Hawkins et al., 1990); the
causes of death, determined from medical records, were
recurrent tumour in 82 (73%), second neoplasm in six (5%)
and other causes in 24 (21%).
Survival rates for children with neuroblastoma were still
low in comparison with most other childhood cancers by
1983-85, despite the substantial improvements which had
taken place, especially since 1980. This was a time which saw
intensive research into treatment for neuroblastoma using
different combinations of cytotoxic drugs with, in some in-
stances, radiotherapy and/or high dose chemotherapy with
autologous bone marrow rescue (Pinkerton, 1990), but no
survival rates have been published from these studies for all
stages combined. The increase in survival rates nationally
might be attributable in part to a rise in the proportion of
early stage tumours but this could not be checked in the
Registry data. The 2-year survival rate of 32% in Denmark
during 1970-80 (Carlsen et al., 1986) was somewhat better
than the 24% in Britain during 1971-79, but 5-year survival
in the United States was appreciably higher than in either
country (Table VI).
Survival rates for retinoblastoma were very high through-
out the period and have been documented in greater detail
elsewhere (Sanders et al., 1988). The continuing mortality at
more than 5 years after diagnosis is due largely to the
occurrence of second primary tumours in survivors of
bilateral retinoblastoma (Draper et al., 1986; Hawkins, 1989).
Survival rates for Wilms' tumour showed a substantial
improvement, particularly in the earlier part of the study
period. Throughout 1971-85 there has been a succession of
clinical trials and studies of Wilms' tumour in Britain,
organised at first by the MRC (MRC, 1978; Morris Jones et
al., 1983) In the early 1970s, children included in the first
MRC trial had a higher survival rate than eligible children
who were not included (Lennox et al., 1979). The category of
Wilms' tumour in our series included children with bone-
metastasising renal tumour of childhood (BMRTC) and
rhabdoid renal tumour. We have identified 25 cases of
BMRTC during the study period, nearly all of them from
national clinical studies. The 3-year survival rate was 68%
overall, and 91% for the 11 children diagnosed during 1980
onwards. These survival rates may well be over estimated as
there could have been other, unidentified children with
BMRTC outside the trials who may have died. Nevertheless,
it is clear that this tumour, which originally had a very poor
prognosis, is now eminently treatable. We have also recorded
14 cases of rhabdoid tumour, all but one of them diagnosed
during 1979 or later. The survival rate 1 year after diagnosis
was only 21%, and only one child has so far survived more
than 5 years. This very grave prognosis is similar to that
observed in the principal clinical trials (Weeks et al., 1989).
The large increase in survival rates for osteosarcoma dur-
ing the most recent triennium has been reported previously
(Stiller, 1988b). The present results, based on a larger
number of patients and an extended period of follow-up,
confirm the trend noted in that preliminary report. The
improvement in prognosis during 1981 onwards was attribut-
able to the much greater improvement for children who were
treated at paediatric oncology centres (Stiller, 1988a). Some
children were entered in clinical trials organised by the
Medical Research Council during 1975-81 (MRC, 1986b)
and EORTC-SIOP during 1978-83 (Burgers et al., 1988).
Survival rates for children were not reported separately in
either study. In the earlier trial, the 5-year survival rate was
27%, with no significant variation by age; in the latter, where
children were stated to have a lower survival rate than adults,
the rate for all ages combined was 43%. Thus the 5-year814 C.A. STILLER & K.J. BUNCH
rates for children in both studies were probably similar to the
25-35% in the present series during the same period. In
comparison with the United States (Table VI), however, the
survival for childhood osteosarcoma in Britain during the
1970s was poor.
The combination of a 5-year survival rate well under 50%
and no increase in survival rates during the study period
which was found in Ewing's sarcoma occurred for no other
diagnostic group. Higher survival rates have been reported
for clinical series in Britain (Graham-Pole, 1979). Population-
based survival rates in the United States were also somewhat
higher than in Britain (Table VI).
The increase in survival rates for rhabdomyosarcoma took
place concurrently with large clinical trials in Europe and the
United States in which various combinations of chemo-
therapy and radiotherapy were evaluated. The 5-year survival
rates reported here were nevertheless appreciably lower than
the 55% in the Intergroup Rhabdomyosarcoma Study (IRS)-
I which was open during 1972-78 (Maurer et al., 1988a), the
52% in the SIOP trial of 1975-82 (Rodary et al., 1988) and
the 62% in IRS-IT of 1978-84 (Maurer et al., 1988b). The
American population-based survival rate was also higher
than that in Britain (Table V), but very similar to those in
IRS-I (Maurer et al., 1988a). The 5-year survival rate for
children treated at two large oncology centres in Britain
during 1974-81 was 58% (Kingston et al., 1983), higher than
in the present series but similar to the American results
(Table VI). The variation in survival rate between primary
sites, with the best prognosis for tumours of the orbit and the
genitourinary sites, was similar to that found in IRS-I and
the SIOP trial (Maurer et al., 1988a; Rodary et al., 1988).
The improvements in survival for germ-cell tumours were
the result of the use of increasingly effective chemotherapy
regimes. The role of chemotherapy in ovarian tumours dur-
ing the first half of the study period has been previously
described (La Vecchia et al., 1983). The improvements in
more recent years were parallel with those in the UKCCSG
germ-cell tumour studies (Mann et al., 1989), in which many
of the children analysed here were entered.
A detailed study of children with carcinomas diagnosed
during 1971-80 has recently been published (McWhirter et
al., 1989). Carcinoma of the thyroid already had an excellent
prognosis. The second most common site was the naso-
pharynx; there was no sign of any increase in survival rates,
despite the recently reported improvement in prognosis for
children treated with adjuvant chemotherapy in conjunction
with radiotherapy (Roper et al., 1986).
The improvements in survival rates for nearly all diagnos-
tic groups described above took place during a period when
increasing numbers of chilren were treated at specialist cen-
tres participating in national and international clinical trials
and studies. It is hoped that this centralisation of care will
pi-ovide the opportunity for further improvements in the
prognosis for many childhood cancers.
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